IL222309A0 - Pharmaceutical formulations for the treatment of overactive bladder - Google Patents
Pharmaceutical formulations for the treatment of overactive bladderInfo
- Publication number
- IL222309A0 IL222309A0 IL222309A IL22230912A IL222309A0 IL 222309 A0 IL222309 A0 IL 222309A0 IL 222309 A IL222309 A IL 222309A IL 22230912 A IL22230912 A IL 22230912A IL 222309 A0 IL222309 A0 IL 222309A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- pharmaceutical formulations
- overactive bladder
- overactive
- bladder
- Prior art date
Links
- 206010020853 Hypertonic bladder Diseases 0.000 title 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title 1
- 208000020629 overactive bladder Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32020210P | 2010-04-01 | 2010-04-01 | |
| PCT/US2011/031020 WO2011123836A2 (en) | 2010-04-01 | 2011-04-01 | Pharmaceutical formulations for the treatment of overactive bladder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL222309A0 true IL222309A0 (en) | 2012-12-31 |
Family
ID=42289923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL222309A IL222309A0 (en) | 2010-04-01 | 2012-10-09 | Pharmaceutical formulations for the treatment of overactive bladder |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9415013B2 (enExample) |
| EP (2) | EP2552417B1 (enExample) |
| JP (4) | JP5903425B2 (enExample) |
| KR (1) | KR101357934B1 (enExample) |
| CN (1) | CN103228267A (enExample) |
| AU (1) | AU2010201841A1 (enExample) |
| BR (1) | BR112012025015B1 (enExample) |
| CA (1) | CA2795257C (enExample) |
| ES (1) | ES2746884T3 (enExample) |
| GB (1) | GB2479213B (enExample) |
| IL (1) | IL222309A0 (enExample) |
| MX (2) | MX349917B (enExample) |
| RU (1) | RU2612022C2 (enExample) |
| SG (2) | SG174658A1 (enExample) |
| WO (1) | WO2011123836A2 (enExample) |
| ZA (1) | ZA201208152B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| GB2479213B (en) | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| WO2012154892A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of propiverine and salivary stimulants for the treatment of overactive bladder |
| WO2012154778A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder |
| WO2012154779A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida. Inc. | Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder |
| AU2012253669A1 (en) * | 2011-05-10 | 2013-11-28 | Theravida, Inc. | Combinations of trospium and salivary stimulants for the treatment of overactive bladder |
| US20120289562A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder |
| WO2012154771A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder |
| EP2706997B1 (en) | 2011-05-10 | 2019-03-27 | TheraVida, Inc. | Combinations of solifenacin and pilocarpine for the treatment of overactive bladder |
| US20120289560A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| KR20150013657A (ko) | 2012-05-01 | 2015-02-05 | 테라비다, 인코포레이티드 | 과민성 방광의 치료 방법 |
| JP2015533174A (ja) * | 2012-10-11 | 2015-11-19 | セラヴィダ，インコーポレイテッド | ピロカルピンの医薬製剤 |
| KR102600541B1 (ko) | 2016-01-20 | 2023-11-08 | 테라비다, 인코포레이티드 | 다한증을 치료하기 위한 방법 및 조성물 |
| KR20180003340A (ko) * | 2016-06-30 | 2018-01-09 | 한미약품 주식회사 | 무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법 |
| PT3856182T (pt) | 2018-09-28 | 2026-03-10 | Karuna Therapeutics Inc | Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos |
| EP4018847B1 (en) | 2020-12-22 | 2024-09-18 | Swedish Match North Europe AB | A pouched product for oral use |
| EP4018849B1 (en) | 2020-12-22 | 2024-10-23 | Swedish Match North Europe AB | A pouched product for oral use |
| US20240350420A1 (en) * | 2021-08-11 | 2024-10-24 | Wayne Stephen ANDREWS | Pharmaceutical compositions and methods for treating hyperhidrosis |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4209505A (en) | 1979-04-03 | 1980-06-24 | Mikhail Adib R | Pilocarpine mouthwash for dry mouth relief |
| US4302440B1 (en) | 1980-07-31 | 1986-08-05 | Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof | |
| SE450087B (sv) | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| AU1806895A (en) | 1994-02-23 | 1995-09-11 | Bm Research A/S | Controlled release composition |
| US5674895A (en) | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO1998030208A1 (en) | 1997-01-10 | 1998-07-16 | Abbott Laboratories | Tablet for the controlled release of active agents |
| CZ295502B6 (cs) | 1997-03-26 | 2005-08-17 | Janssen Pharmaceutica N. V. | Antifungální peleta, způsob její přípravy a farmaceutická dávková forma s obsahem těchto pelet |
| CN1204890C (zh) | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
| TR200001942T2 (tr) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid agonist/antagonist kombinasyonlar |
| US6482837B1 (en) | 1998-04-24 | 2002-11-19 | University Of Rochester | Antimuscarinic compounds and methods for treatment of bladder diseases |
| US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| CA2347104A1 (en) | 1998-10-26 | 2000-04-05 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
| FR2795962B1 (fr) | 1999-07-08 | 2003-05-09 | Prographarm Laboratoires | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif |
| JP2003509439A (ja) * | 1999-09-14 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | 水性コーティングされたビーズレットの製法 |
| DK1227806T3 (da) | 1999-11-11 | 2005-10-31 | Pfizer Health Ab | Farmaceutisk præparat indeholdende tolterodin og dets anvendelse |
| EP1258253A1 (en) | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US6419954B1 (en) | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| DE60322371D1 (de) | 2002-03-29 | 2008-09-04 | Alza Corp | Volumensparende arzneiform zur kontrollierten freisetzung |
| FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
| FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
| US9107804B2 (en) * | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
| EP1635795A1 (en) * | 2003-05-30 | 2006-03-22 | Ranbaxy Laboratories, Ltd. | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
| EP1651192A1 (en) | 2003-08-06 | 2006-05-03 | Nirmal Mulye | Pharmaceutical composition containing water soluble drug |
| DE602004030931D1 (enExample) * | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| WO2006026556A2 (en) | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Bioadhesive rate-controlled oral dosage formulations |
| RU2382637C2 (ru) * | 2004-04-30 | 2010-02-27 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию |
| CA2566311A1 (en) | 2004-05-19 | 2005-12-08 | Glatt Air Techniques, Inc. | Micropellet containing pellets and method of preparing such pellets |
| WO2005123042A1 (en) * | 2004-06-10 | 2005-12-29 | Glatt Air Techniques, Inc. | Controlled release pharmaceutical formulation |
| EP1629834A1 (en) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| WO2006132196A1 (ja) | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β３作動薬を含有する新規な医薬 |
| RU2435610C2 (ru) | 2005-09-02 | 2011-12-10 | Теравида, Инк. | Терапия для лечения заболевания |
| WO2007029087A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Controlled release multiple unit formulations |
| US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
| WO2007046102A2 (en) | 2005-10-19 | 2007-04-26 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
| AU2008288105A1 (en) | 2007-03-29 | 2009-02-19 | Panacea Biotec Limited. | Modified dosage forms of tacrolimus |
| US7563508B2 (en) * | 2007-05-30 | 2009-07-21 | Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. | Diffusion beads with core-shell structure |
| CL2008001970A1 (es) * | 2007-07-03 | 2009-03-27 | Synthon Bv | Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. |
| US8110226B2 (en) | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
| US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| EP2205279B1 (en) * | 2007-09-28 | 2011-04-13 | Novartis AG | Pharmaceutical combination of aliskiren and valsartan |
| JP2011502140A (ja) * | 2007-10-29 | 2011-01-20 | ルピン・リミテッド | トルテロジンの制御放出型医薬組成物 |
| US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| WO2009151712A2 (en) | 2008-03-25 | 2009-12-17 | Auspex Pharmaceuticals. Inc. | Substituted phenylcyclohexylglycolates |
| GB2479213B (en) | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| CA2795253A1 (en) | 2010-04-01 | 2011-10-06 | Theravida, Inc. | Methods of improving quality of sleep |
| EP2706997B1 (en) | 2011-05-10 | 2019-03-27 | TheraVida, Inc. | Combinations of solifenacin and pilocarpine for the treatment of overactive bladder |
| US20120289560A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| US20140037713A1 (en) | 2012-08-03 | 2014-02-06 | Antares Pharma Ipl, Ag | Transdermal compositions for anti-cholinergic agents |
| JP2015533174A (ja) | 2012-10-11 | 2015-11-19 | セラヴィダ，インコーポレイテッド | ピロカルピンの医薬製剤 |
| KR102600541B1 (ko) | 2016-01-20 | 2023-11-08 | 테라비다, 인코포레이티드 | 다한증을 치료하기 위한 방법 및 조성물 |
-
2010
- 2010-04-30 GB GB1007279.1A patent/GB2479213B/en active Active
- 2010-04-30 SG SG2010030609A patent/SG174658A1/en unknown
- 2010-05-06 AU AU2010201841A patent/AU2010201841A1/en not_active Abandoned
-
2011
- 2011-04-01 RU RU2012143705A patent/RU2612022C2/ru active
- 2011-04-01 WO PCT/US2011/031020 patent/WO2011123836A2/en not_active Ceased
- 2011-04-01 BR BR112012025015-9A patent/BR112012025015B1/pt not_active IP Right Cessation
- 2011-04-01 CN CN2011800213642A patent/CN103228267A/zh active Pending
- 2011-04-01 JP JP2013502906A patent/JP5903425B2/ja active Active
- 2011-04-01 EP EP11763548.2A patent/EP2552417B1/en active Active
- 2011-04-01 EP EP18212881.9A patent/EP3482746A1/en not_active Withdrawn
- 2011-04-01 MX MX2012011397A patent/MX349917B/es active IP Right Grant
- 2011-04-01 KR KR1020117018984A patent/KR101357934B1/ko not_active Expired - Fee Related
- 2011-04-01 MX MX2017010704A patent/MX391480B/es unknown
- 2011-04-01 US US13/078,881 patent/US9415013B2/en active Active
- 2011-04-01 ES ES11763548T patent/ES2746884T3/es active Active
- 2011-04-01 SG SG2012072963A patent/SG184388A1/en unknown
- 2011-04-01 CA CA2795257A patent/CA2795257C/en active Active
-
2012
- 2012-04-17 US US13/449,284 patent/US20120201894A1/en not_active Abandoned
- 2012-10-09 IL IL222309A patent/IL222309A0/en unknown
- 2012-10-30 ZA ZA2012/08152A patent/ZA201208152B/en unknown
-
2015
- 2015-11-20 JP JP2015227923A patent/JP5903522B1/ja active Active
-
2016
- 2016-03-14 JP JP2016049170A patent/JP6258382B2/ja active Active
- 2016-07-06 US US15/203,699 patent/US9968556B2/en active Active
-
2017
- 2017-12-06 JP JP2017234012A patent/JP6561105B2/ja active Active
-
2018
- 2018-04-10 US US15/949,911 patent/US10786457B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2479213B (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| PL2560624T3 (pl) | Formulacja terapeutyczna do zmniejszania skutków ubocznych leku | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| RS67768B1 (sr) | Terapijski agens koji indukuje citotoksičnost | |
| SI3378862T1 (sl) | Dihidropirimidinoizokuinolini in farmacevtski sestavki le-teh za zdravljenje multiple skleroze | |
| ZA201208646B (en) | Pharmaceutical combination for the treatment of pain | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| HRP20181896T1 (hr) | Farmaceutske formulacije | |
| GB2486567B (en) | Pharmaceutical formulation | |
| ZA201301458B (en) | Therapeutic agent for pain | |
| IL200753A (en) | Pharmaceutical preparation containing ib – meca for the treatment of psoriasis | |
| GB201013573D0 (en) | Treatment | |
| ZA201300083B (en) | New drug combinations for the treatment of malaria | |
| WO2012158942A9 (en) | Drug treatment of overactive bladder | |
| IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| IL238071B (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease | |
| HUP1100534A2 (en) | Pharmaceutical composition for the treatment of muscle atrophy | |
| GB201012046D0 (en) | Pharmaceutical formulations | |
| GB201012047D0 (en) | Pharmaceutical formulations | |
| IL232294A0 (en) | Preparations for the treatment of diabetes | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds | |
| PT2812351T (pt) | Composição farmacêutica para o tratamento de esclerose múltipla | |
| GB201003727D0 (en) | Therapeutic agent | |
| GB201009614D0 (en) | Therapeutic use of compounds | |
| GB201111577D0 (en) | Pharmaceutical formulations |